title: [An update on the management of chronic hepatitis C].
abstract: Treatment of chronic hepatitis C with pegylated interferon-a and ribavirin is now adapted individually based on the virological response on treatment. This approach should improve the tolerability while maintaining or even improving in some patients the efficacy of antiviral therapy. Several new antiviral drugs are currently being evaluated in advanced clinical trials, with very promising results. These new drugs should greatly broaden treatment options for chronic hepatitis C in the near future.
authors.affiliation: Service de gastro-entérologie et d'hépatologie, CHUV, 1011 Lausanne. Florian.Bihl@chuv.ch
authors.forename: F
authors.initials: F
authors.lastname: Bihl
authors.forename: I
authors.initials: I
authors.lastname: Pache
authors.forename: J
authors.initials: J
authors.lastname: Hess
authors.forename: D
authors.initials: D
authors.lastname: Moradpour
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001706:Biopsy; D024882:Drug Resistance, Viral; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D008099:Liver / Q000473:pathology
chemical_list: D000998:Antiviral Agents